Race is not associated with the development of metastases in patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to a study published in the journal Cancer.1
Despite race being associated with disease progression in patients with early stage prostate cancer, how race contributes to outcomes in men who already have advanced disease is unclear.
Therefore, researchers sought to assess whether black men with CRPC and no known metastases would have a higher risk of metastatic disease in an equal-access setting.
For the study, investigators analyzed data from 837 men with M0/Mx CRPC diagnosed between 2000 and 2014 and received care at 5 Veteran Affairs hospitals.
Results showed that the 306 black men were equally as likely as the 531 nonblack men to receive a first and second bone scan following diagnosis of CRPC.
The study demonstrated no significant differences in the risk of metastasis development, bone metastases, time to bone scans, or overall survival between black patients and nonblack patients (all P >.2).
The findings ultimately suggest that studies seeking to understand prostate cancer racial disparities may derive greater benefit by evaluating the impact of race on the risk of developing prostate cancer and on the outcomes of patients with early stage disease.
1. Whitney CA, Howard LE, Amling CL, et al. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer. Cancer. 2016 Aug 9. doi: 10.1002/cncr.30221. [Epub ahead of print]